Psyence Group (TSE:PSYG) has released an update.
Psyence Group has announced a deal to sell its 11.13% interest in PsyLabs to Psyence Biomed, which will bolster Psyence Biomed’s capabilities in developing psychedelic-based therapeutics. The agreement, valued at $1.1 million in common stock, is contingent on certain conditions including approvals and a product development milestone by PsyLabs.
For further insights into TSE:PSYG stock, check out TipRanks’ Stock Analysis page.
